PMN 442
Alternative Names: PMN-442; α-Syn targeting antibody - ProMIS NeurosciencesLatest Information Update: 07 Jun 2023
Price :
$50 *
At a glance
- Originator ProMIS Neurosciences
- Class Antiparkinsonians; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Movement disorders; Parkinson's disease